The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens

K. A. Mundt 1*, L. D. Dell 2, P. Boffetta 3,4, E. M. Beckett 1, H. N. Lynch 1, V. J. Desai 5, C. K. Lin 1 and W. J. Thompson 1

Abstract

Introduction: Although myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) – including chronic myeloid leukemia (CML) – and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are largely clinically distinct myeloid malignancies, epidemiological studies rarely examine them separately and often combine them with lymphoid malignancies, limiting possible etiological interpretations for specific myeloid malignancies.

Methods: We systematically evaluated the epidemiological literature on the four chemical agents (1,3-butadiene, formaldehyde, benzene, and tobacco smoking, excluding pharmaceutical, microbial and radioactive agents, and pesticides) classified by the International Agency for Research on Cancer as having sufficient epidemiological evidence to conclude that each causes “myeloid malignancies.” Literature searches of IARC Monographs and PubMed identified 85 studies that we critically assessed, and for appropriate subsets, summarized results using meta-analysis.

Results: Only two epidemiological studies on 1,3-butadiene were identified, but reported findings were inadequate to evaluate specific myeloid malignancies. Studies on formaldehyde reported results for AML and CML – and not for MDS or MPN – but reported no increased risks. For benzene, several specific myeloid malignancies were evaluated, with consistent associations reported with AML and MDS and mixed results for CML. Studies of tobacco smoking examined all major myeloid malignancies, demonstrating consistent relationships with AML, MDS and MPN, but not with CML.

Conclusions: Surprisingly few epidemiological studies present results for specific myeloid malignancies, and those identified were inconsistent across studies of the same exposure, as well as across chemical agents. This exercise illustrates that even for agents classified as having sufficient evidence of causing “myeloid malignancies,” the epidemiological evidence for specific myeloid malignancies is generally limited and inconsistent. Future epidemiological studies should report findings for the specific myeloid malignancies, as combining them post hoc – where appropriate – always remains possible, whereas disaggregation may not. Furthermore, combining results across possibly discrete diseases reduces the chances of identifying important malignancy-specific causal associations.

Keywords: Myeloid, AML, MDS, CML, MPN, Epidemiology, Benzene, Formaldehyde, 1,3-butadiene, Tobacco smoking

* Correspondence: Kenneth.Mundt@cardno.com
1Cardno ChemRisk, Boston, MA, USA
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Hematopoietic and lymphoid malignancies (also known as lymphohematopoietic malignancies, or LHM) arise from stem and progenitor cells derived from hematopoietic stem cells. These diseases, though, represent several heterogeneous groups of neoplasms that are biologically, etiologically or clinically distinct [1]. LHM are classified based on the progenitor cells from which they arise, the vast majority being of lymphoid (i.e., derived from the lymph and lymphatic system) or myeloid (deriving from the bone marrow) origin, although much rarer malignancies may arise from dendritic or histiocytes.

Lymphoid malignancies generally are associated with lymphoid progenitor cells that mature into cells of the immune system, including B lymphocytes [B-cells], T lymphocytes [T-cells], and Natural Killer [NK] cells, but are categorized by the stage of differentiation of the tumor cells rather than the cell in which the initial transforming event occurred [2]. Lymphoid malignancies include various lymphomas, as well as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Myeloid malignancies arise from myeloid progenitor cells and include all granulocytic (e.g., erythrocytes, or red blood cells) and mast cell lineages [3]. Myeloid malignancies include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML, which has replaced the term acute nonlymphocytic leukemkia, ANLL), myeloproliferative neoplasms (MPN), chronic myeloid (or “myelogenous”) leukemia (CML) – and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) [2]. Multiple myeloma is a malignant disorder involving plasma cells which originate from B-cells. Most of these sub-groups of LHM contain multiple entities with diverse etiologies and possible underlying risk factors.

The 2008 revision of the World Health Organization (WHO) classification of LHMs led to changes in the classification of leukemias and especially myeloid leukemias for epidemiological research based on improved understanding of the lineage of the cells, as well as the molecular genetics and pathologic characteristics of the different malignancies. The WHO classification was further updated in 2016 for lymphoid [4] and for myeloid malignancies [5].

The primary objective of this paper is to evaluate the published epidemiological evidence on the myeloid malignancies – especially AML and MDS – than for leukemias as a group or lymphoid malignancies, which are generally more closely related to infections and immunological functions [6].

PART I: overview of the myeloid malignancies
Since 2001, the WHO has included genetic information relevant to the diagnosis and classification of LHMs, and the 2008 WHO classification of myeloid neoplasms built on the 2001 classification. The underlying pathology in myeloid malignancies is based on clonal proliferations arising in hematopoietic stem or progenitor cells, and specific diseases are often associated with genetic or epigenetic changes in genes involved in regulation of cell growth. The 2016 update to the 4th Edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues additionally incorporated clinical features, morphology, immuno-phenotyping, cytogenetics, and molecular genetics to classify both acute and chronic myeloid leukemias into subtypes and discrete disease entities of clinical significance [7]. A brief review of the current pathology and classification of the myeloid malignancies illustrates several ways in which specific myeloid malignancies differ and a basis for epidemiologically examining them separately (Part II).

Myelodysplastic syndromes (MDS)
MDS refers to a heterogeneous collection of clonal disorders of pluripotent hematopoietic progenitor cells (HPC) that demonstrate lower than normal blood cell counts (cytopenias), an increased percentage of blasts in bone marrow, and dysplasia in erythroid cells, granulocytes, or megakaryocytes [5]. MDS generally has an insidious onset, often diagnosed due to vague symptoms arising as a manifestation of cytopenias, and a variable prognosis, depending upon the molecular genetic profile of the subtype and individual response to therapy. Approximately 20–30% of MDS patients over the age of 65 go on to develop AML, suggesting that at least some proportion of these cases may represent the same underlying disease processes or share causal factors [8]. Some acquired mutations seen in the development of MDS include those in genes involved in RNA splicing (SRSF2), DNA methylation (DNMT3a, TET2, IDH 1/2), chromatin modification (ASXL1) or the cohesion complex (STAG2) [9].

MDS is more prevalent in older adults, with the majority of cases diagnosed in individuals over the age of 60 [10]. Rates of MDS appear to be increasing, which may be due to improvements over time in diagnostic specificity combined with clearer diagnostic criteria for MDS [11].
Acute myeloid leukemia (AML)
The classification of AML includes 20 definitive and 2 provisional subtypes [5]. AML generally has a rapid onset, often diagnosed due to the development of infections, bleeding, or fatigue that result from pancytopenia, and a variable prognosis, depending upon the molecular genetic profile of the subtype and individual response to therapy.

AML is a genetically diverse disease, with 40–55% of patients having chromosome abnormalities that can be identified using conventional analysis techniques [12–14]. The most common genetic change is the loss of genetic material in chromosome 5 or chromosome 7 [13]. Others include deletions in parts of chromosomes (e.g., the long arms of chromosomes 5, 7, and 9), insertion of genetic material, inversions of genetic material (e.g., involving chromosome 16), duplications, and translocations (e.g., t[8;21], t[15;17], and 11q23 translocation) [13]. Approximately 40–50% of AML patients have a normal karyotype and harbour mutations within specific genes including IDH1, IDH2, FLT3, and NPM1.

Some AMLs develop secondary to MDS, and these occur in patients with acquired mutations in genes encoding for myeloid transcription factors (RUNX1, CEBPA) or signal transduction proteins (FLT3) [9]. However, de novo AMLs are also diagnosed in patients with mutations in RUNX1, CEBPA, FLT3 or MLL, but these patients do not have mutations in the genes associated with prior MDS (described above) [9]. Estey (2018) estimated that one-third of patients clinically diagnosed with de novo AML will exhibit genetic mutations specific for secondary AML [9].

AML is more common in the elderly, with more than 58% of cases diagnosed among those 65 years of age or older [10].

Myeloproliferative neoplasms (MPN)
MPNs (previously known as myeloproliferative disorders, or MPD) are a group of clonal hematopoietic neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). These conditions are associated with the proliferation of one or more of the myeloid lineages (i.e., increased blood cell counts), without dysplasia. CML shares several features with these disorders, e.g., dysregulated production of a particular lineage of mature myeloid cells, a tendency to progress to acute leukemia, and abnormalities in thrombosis and hemostasis. Many diagnoses of MPNs occur in patients that have acquired mutations in the Janus kinase 2 (JAK2) gene, seen in 95% of patients diagnosed with PV and over 50% of patients diagnosed with MF and ET) [15]. Other mutations seen in patients with MPN include calreticulin (CALR), myeloproliferative leukemia virus oncogene (MPL) [16].

SEER data are limited for MPN, however, ET represented 45.5% of the cases and PV accounted for 41.5% of the cases. The incidence rate was slightly higher in males compared to females, 3.3 vs. 3.0 per 100,000, respectively. Incidence rates increased with age from 0.5 per 100,000 for under age 40 to 18.6 per 100,000 for ages 80 and over [10].

Chronic myeloid leukemia (CML)
In CML, the proliferating cells are mature cells of the myeloid lineage, which have differentiated into functional formed elements of the blood. The development of CML involves an acquired cytogenetic abnormality in the pluripotent hematopoietic stem cells (HSCs) or myeloid progenitor cells located in the bone marrow. Ninety-five percent of CML cases involve the reciprocal translocation of genetic material between chromosome 22 and chromosome 9 (t(9;22)(q34;q11)). This translocation results in an abnormally shortened version of chromosome 22, known as the “Philadelphia (Ph) chromosome” [17, 18].

In the United States, the median age at diagnosis of CML was 65 years, while the median age at death was 77 years. The incidence rate among males, for all races and ethnicities and all age-groups, was 2.4 per 100,000 population, while among females the rate was 1.4 per 100,000. Incidence among white males was 2.5 per 100,000 while the incidence was 2.2 per 100,000 among black males. Incidence among those under 65 years of age was 1.1 per 100,000 population, but nearly seven times higher (i.e., 7.6 per 100,000) among those 65 and over. Incidence among the population aged 65 and over was highest among white males (11.1 per 100,000), followed by black males (8.2 per 100,000), white females (5.7 per 100,000) and black females (4.9 per 100,000) [10].

Myelodysplastic syndrome/Myeloproliferative Neoplasms (MDS/MPN)
The 2016 Classification of LHM includes a category for MDS/MPN. These neoplasms are characterized by both dysplastic and proliferative features. Examples include chronic myelomonocytic leukemia (CMLL), atypical chronic myeloid leukemia (aCMLL) and juvenile myelomonocytic leukemia (JML) [7]. However, these specific myeloid neoplasms are very rare and infrequently considered in epidemiological studies; therefore, they are not discussed further.

PART II: epidemiological evaluation of four environmental agents and specific myeloid malignancies

Methods
We reviewed the list of carcinogenicity classifications by cancer site published on the IARC Monographs website.
The IARC has identified 28 agents as having sufficient evidence of carcinogenicity in humans for neoplasms the IARC grouped as “leukemia and/or lymphoma”. We assessed the human evidence summaries in the “Evaluation” sections of the relevant IARC monographs for each agent.

We excluded from our review 10 pharmaceutical agents (azathioprine, busulfan, chlorambucil, cyclophosphamide, etoposide with cisplatin and bleomycin, melphalan, MOPP [vincristine-prednisone-nitrogen mustard-procarbazine], semustine [methyl-CCNU], thiotepa, and treosulfan) because most of these are chemotherapy agents in which exposure is voluntary and the expected benefit likely offsets the possible leukemogenic effect. We also eliminated radioactive (e.g., X- and gamma radiation, fission-products radionuclides [including strontium-90], thorium-232 and its decay products) and microbiological (Epstein Barr virus, helicobacter pylori, hepatitis C virus, Human immunodeficiency virus type 1, Human T-cell lymphotropic virus type 1, Kaposi sarcoma herpes virus) agents. We excluded two pesticides - pentachlorophenol and lindane - because IARC identified the human evidence as sufficient for causing NHL (lymphomas). We also excluded IARC’s evaluation “occupational exposures in the rubber-manufacturing industry” because workers in the industry are exposed to multiple chemicals and it cannot be determined which specific agents may be causally related to leukemia.

After these exclusions, four leukemogenic chemical agents remained: 1,3-butadiene, formaldehyde, benzene and tobacco smoking. For each of these, we conducted a focused systematic review of the literature using searches of the relevant IARC Monographs and key word searches of PubMed to identify epidemiological studies that reported results separately for specific subtypes of myeloid malignancies. Keywords included “benzene”, “1,3-butadiene,” “formaldehyde,” “cigarette,” “smoking,” “leukemia,” “myeloid,” “AML,” “CML,” “MDS,” and “MDN.” Where results of independent studies of acceptable quality were available, we conducted meta-analyses using random-effects models [21]. For each study, the following characteristics were extracted consistent with PRISMA guidelines [22]: study design, study population, geographic location, study period, exposure categories, number of deaths observed or number of cases in exposed and unexposed groups, relative risk measures (SMRs, HRs, RRs, and ORs) 95% confidence intervals (CI) and covariates adjusted for in models. Using meta-analysis, summary relative risk estimates were calculated by specific categories of myeloid malignancy including AML, CML and MDS. Cohort studies and case-control studies were analysed separately as well as overall and where possible for the highest exposure categories. When multiple results were published on the same study population, we preferentially selected for meta-analysis those based on incidence data, those representing the most complete results, or results reported for higher exposure categories. Publication bias was assessed using a visual inspection of the funnel plots as well as Egger’s test (see supplemental file). Heterogeneity was evaluated using the I² statistic, which provides a measure for quantifying inconsistency of effects across studies. All meta-analyses were conducted using R version 3.6.1 (2019-07-05).

**Results**

### 1,3-butadiene (butadiene)

The IARC last reviewed the carcinogenicity of butadiene in 2009 [23]. The epidemiological evidence for exposure to butadiene and risk of leukemia is based primarily on studies conducted among workers in the butadiene monomer industry and workers in the styrene–butadiene rubber (SBR) manufacturing industry. However, results on specific types of leukemia are available only from studies conducted in the SBR manufacturing industry.

A study of approximately 17,000 workers from eight SBR facilities across the United States and Canada reported an increased risk of leukemia among 16,610 workers (12,412 exposed to butadiene), based on 58 leukemia deaths [24]. Because standardized mortality ratio analyses were not conducted, it is not clear whether excess mortality from leukemias occurred. A positive dose-response was reported between cumulative exposure to butadiene and risk of leukemia. Despite the individual exposure estimates and the relatively large number of leukemia deaths, results by leukemia subtype were not reported.

The mortality follow-up was extended through 1998 for 15,649 men employed since 1943, 75% of whom were exposed to butadiene [25]. A total of 71 deaths from leukemia was observed (SMR 1.16, 95% CI, 0.91–1.47). No consistent patterns were observed by categories of years since hire or by years worked. The excess leukemia mortality was concentrated among men hired in the 1950s (31 deaths; SMR, 1.50; 95% CI, 1.01–2.11). In the analysis by leukemia subtype the SMR was 1.02 (95% CI 0.56–1.71, 14 deaths) for AML and 1.67 (95% CI 0.83–2.99, 11 deaths) for CML. Mortality from AML was elevated in maintenance laborers and from CML in laboratory workers; however these were based on only five and three deaths, respectively.

Time-dependent exposure-response relationships between several butadiene exposure indices and leukemia (81 decedents) as well as all myeloid neoplasms (56 decedents from myeloid and monocytic leukemia, myelofibrosis, myelodysplasia, myeloproliferative disorders and polycythemia vera) were evaluated [26]. The butadiene
exposure indices included cumulative exposure in ppm-years, total number of exposures to peaks (> 100 ppm) and average intensities of exposure in parts per million. All three exposure indices were associated positively with the risk for leukemia whereas the myeloid neoplasms were more clearly associated with peak exposures. This highlights the potential additional role choice of exposure metric may play in evaluating risk [27].

Only two studies evaluated the risk of myeloid malignancies [25, 26], based on the same study cohort. Risks of AML were not increased, and risk of CML was increased but not statistically significantly. For myeloid leukemias (including CML), a relationship was reported for peak exposure, but not cumulative exposure.

**Formaldehyde**

The IARC last reviewed the carcinogenicity of formaldehyde in 2009 (23). The epidemiological literature on exposure to formaldehyde and risk of leukemia published since the IARC meeting was reviewed in detail [28]. Twenty studies that reported results for leukemia overall were included, three of which also reported results for myeloid leukemia. Since then, some of the occupational epidemiological studies have been updated or re-analyzed, and new studies have been published that examine myeloid leukemias in relation to formaldehyde exposure (Table 1).

Peak exposure in a cohort of workers employed in six plants producing formaldehyde in the United States was re-defined and analysed with respect to specific leukemia types. Absolute peak exposure, duration of time worked at the highest peak or time since highest peak exposure generated no clear associations with myeloid leukemia or AML. Cumulative exposure also was unrelated to risk of leukemia, myeloid leukemia, AML, or CML. The authors concluded, “Findings from this re-analysis do not support the hypothesis that formaldehyde is a cause of AML” [31]. The use of peak exposure in this and other epidemiological studies presents specific challenges that have been explored separately [27].

The other occupational cohort study of formaldehyde producers also reported no clear associations between different metrics of formaldehyde exposure and myeloid leukemia [30]. In a study of garment workers in the United States [29, 35], moderately elevated relative risks for myeloid leukemia were associated with duration of employment, a surrogate for cumulative exposure, and duration of follow-up, a surrogate for latency. A large cancer registry study in the Nordic countries “did not provide clear evidence for an association between occupational solvent exposure and AML” [34].

There were no deaths from myeloid leukemias among a cohort of laminated plastic workers from Italy [36]. A European community-based cohort study [33] found no increased risks of AML or CML among study subjects with low-level occupational exposure to formaldehyde (no study subjects were reported to have high occupational exposure to formaldehyde).

SMR results for myeloid leukemia, AML and CML, including those for the highest categories of exposure from the most recent updates of the industrial cohorts, are summarized in Table 2. Overall, the updated cohort study analyses demonstrate no clear or consistent excess risk of myeloid leukemia or AML or CML. None of the formaldehyde studies evaluated MDS or MPN. Table 3 presents meta-analysis results by myeloid malignancy, specifically ML, AML and CML. No statistically significant increased meta-relative risk estimates were seen. Based on the I² test, heterogeneity was low, and based on Egger’s test, publication bias appears unlikely.

**Benzene**

The IARC last reviewed the carcinogenicity of benzene in 2018 [6]. Risk estimates for one or more

| Reference | Study design | Population or Cases / controls | Study setting | Years of follow-up | Adjusted for smoking |
|-----------|-------------|---------------------------------|---------------|------------------|---------------------|
| Meyers 2013 [29] | Occupational cohort | 11,098 garment manufacturing workers | US: Georgia and Pennsylvania | 1960–2008 | No |
| Coggon 2014 [30] | Occupational cohort | 14,008 chemical factory workers | UK: England and Wales | 1941–2012 | No |
| Checkoway 2015 [31] | Occupational cohort | 25,619 workers at formaldehyde using or producing plants | US: Re-analysis of Beane Freeman 2009 | 1943–2004 | No |
| Beane Freeman 2009 [32] | Occupational cohort | 25,619 workers at formaldehyde using or producing plants | US: 10 industrial plants | 1943–2004 | No |
| Saberi Hosjineh 2013 [33] | Population-based cohort | 241,465 adults (European Prospective Investigation into Cancer and Nutrition cohort) | 10 European countries: Denmark, France, Greece, Germany, Italy, The Netherlands, Norway, Spain, Sweden, and the UK | 1992–2010 | Yes |
| Talibov 2014 [34] | Population-based case-control | 14,982 AML cases 74,505 controls | 4 Nordic countries: Finland, Norway, Sweden, and Iceland | 1960–2005a | No |

a Study period varies by country
myeloid malignancies were reported in 31 independent
studies. Characteristics of the design of these
studies are summarized in Table 4, and results are
summarized in Table 5.

A cohort exposed to benzene in a variety of manu-
facturing and user industries, including paints and
painting, printing, footwear, paints, chemicals in 12
cities in China was followed for mortality. In the
most recent update of this cohort, 73 leukemia
deaths were observed, including 60 among benzene-
exposed workers [51]. Similar risks were reported for
AML and CML, while the risk of MDS was inestim-
able due to zero cases of MDS among the unexposed
group (Table 5). A case-cohort analysis of combined
AML/MDS (44 cases) and CML (18 cases) from the
12-city China cohort examined the timing of expos-
ure [66]. The investigators found that high cumula-
tive exposure or high intensity exposure experienced
2 to 10 years before diagnosis increased the risk of
MDS/AML among workers who were first exposed
under 30 years of age, but not for workers first ex-
posed 30 years of age or older [66].

Pooled results for AML, CML, MDS and MPN were
reported using data from three separate nested case-
control studies of petroleum workers from Canada,
the UK, and Australia. No significantly elevated risks of
AML by cumulative exposure, average exposure inten-
sity, maximum exposure intensity, duration of employ-
ment, and peak exposure were reported [55]. Increased
relative risk of MDS for cumulative exposure greater
than 2.93 ppm-years and peak exposure less than 3 ppm
were reported, but not for CML or MPN [58]. The most
recent follow-up of incidence in the UK petroleum dis-
tribution and oil refinery workers reported deficits of
MDS [67]. Similarly, the most recent mortality follow-up

| Table 2 | Formaldehyde exposure and risk of specific types of myeloid malignancy by exposure category |
|-----------|----------------------------------|
| Reference | Exposure Category | Myeloid leukemia | AML | CML |
| | | No. of cases | Point estimate | 95% CI | No. of cases | Point estimate | 95% CI | No. of cases | Point estimate | 95% CI |
| Overall Results in Most Informative Cohorts | | | | | | | | | |
| Meyers 2013 [29] | Exposed | 21 | 1.28 | 0.79–1.96 | 14 | 1.22 | 0.67–2.05 | 5 | 1.35 | 0.44–3.15 |
| Coggon 2014 [30] | Exposed | 36 | 1.20 | 0.84–1.66 | | | | | |
| Checkoway 2015 [31] | Exposed | 44 | 0.86 | 0.64–1.16 | 30 | 0.80 | 0.56–1.14 | 13 | 0.97 | 0.56–1.67 |
| Results of Category at Highest Exposure in Studies | | | | | | | | | |
| Beane Freeman 2009 [32] | Peak exposure > 4 ppm | 19 | 1.78 | 0.87–3.64 | | | | | |
| Checkoway 2015 [31] | Peak exposure > 4 ppm | 10 | 1.80 | 0.85–3.79 | 6 | 1.43 | 0.56–3.63 | 4 | 3.07 | 0.83–11.40 |
| Cumulative exposure > 2.5 ppm-yrs | 14 | 0.94 | 0.47–1.86 | 10 | 0.96 | 0.43–2.16 | 4 | 0.92 | 0.25–3.36 |
| Coggon 2014 [30] | High exposure, > one year | 50 | 0.96 | 0.24–3.82 | | | | | |
| Saberi Hosjineh 2013 [33] | 2Low exposure | N/A | 1.01 | 0.65–1.57 | N/A | 0.92 | 0.46–1.84 |
| Meyers 2013 [29] | Duration of exposure 10 + yrs. | 10 | 1.84 | 0.88–3.38 | 7 | 1.81 | 0.73–3.73 | | | |
| Talibov 2014 [34] | Cumulative exposure > 1.6 ppm-yrs | 424 | 1.17 | 0.91–1.51 | | | | | |

| Table 3 | Meta-analysis of formaldehyde exposure and risk of specific types of myeloid leukemia in the most informative cohorts |
|-----------|----------------------------------|
| Characteristics | No. of estimates | Meta-RR estimate (95%CI) | I² test (%) | p-value | Egger’s test |
| ML | | | | | |
| High exposure | 3 | 1.28 (0.81–2.02) | 0.00 | 0.2874 | 0.7851 |
| Any exposure | 3 | 1.05 (0.85–1.30) | 8.85 | 0.6622 | 0.4056 |
| AML | | | | | |
| High exposure | 4 | 1.15 (0.94–1.41) | 0.00 | 0.1808 | 0.8301 |
| Any exposure | 2 | 0.90 (0.67–1.22) | 0.00 | 0.5063 | NA |
| CML | | | | | |
| High exposure | 2 | 0.92 (0.50–1.70) | 0.00 | 0.7893 | NA |
| Any exposure | 2 | 1.05 (0.65–1.69) | 0.00 | 0.8458 | NA |
| Reference       | Study design         | Population or Cases / controls | Study setting                  | Years of follow-up | Adjusted for smoking |
|-----------------|----------------------|--------------------------------|--------------------------------|--------------------|----------------------|
| Adegoke 2003    | Population-based    | 236 AML cases; 79 CML cases     | China: Shanghai               | 1987–1989          | No                   |
| [37]            | case-control         | 502 controls                    |                                |                    |                      |
| Albin 2003      | Population-based    | 330 MDS cases                   | Southern Sweden               | 1976–1993          | No*                  |
| [38]            | case-control         | 337 controls                    |                                |                    |                      |
| Blair 2001      | Population-based    | 132 AML cases; 46 CML cases; 58 MDS cases | USA: Iowa and Minnesota      | 1976–1993          | Yes                  |
| [39]            | case-control         | 1087 controls                   |                                |                    |                      |
| Bjork 2001      | Population-based    | 226 CML cases                   | Southern Sweden               | 1980–1984          | No*                  |
| [40]            | case-control         | 251 controls                    |                                |                    |                      |
| Bonzini 2019    | Occupational cohort | 5112 oil refinery workers       | Italy                         | 1976–1993          | No                   |
| [41]            |                      |                                |                                |                    |                      |
| Collins 2015    | Occupational cohort | 2266 chemical workers           | USA: Michigan                 | 1944–1977          | No                   |
| [42]            |                      |                                |                                |                    |                      |
| Copley 2017     | Hospital-based case control | 604 MDS cases; 1193 controls | China: Shanghai               | 2003–2007          | No*                  |
| [43]            | control              |                                |                                |                    |                      |
| Costantini 2008 | Population-based    | 142 AML cases; 893 controls     | Italy                         | 1991–1993          | No*                  |
| [44]            | case-control         |                                |                                |                    |                      |
| Divine 1999     | Occupational cohort | 28,480 oil refinery and         | USA: Texas                    | 1947–1993          | No                   |
| [45]            |                      | petrochemical workers           |                                |                    |                      |
| Divine 2000     | Occupational cohort | 24,124 oil production and       | USA                            | 1946–1994          | No                   |
| [46]            |                      | pipeline workers                |                                |                    |                      |
| Guenel 2002     | Nested case-control | 26 AML cases; 103 controls      | France                        | 1978–1989          | No                   |
| [47]            |                      |                                |                                |                    |                      |
| Huebner 2009    | Occupational cohort | 127,266 petroleum workers       | USA: Louisiana and Texas      | 1979–2000          | No                   |
| [48]            |                      |                                |                                |                    |                      |
| Ireland 1997    | Occupational cohort | 4172 chemical workers           | USA: Illinois                 | 1940–1991          | No                   |
| [49]            |                      |                                |                                |                    |                      |
| Kirkeleit 2008  | Occupational case-  | 27,919 upstream petroleum       | Norway                        | 1981–2003          | No                   |
| [50]            | control              | workers                         |                                |                    |                      |
| Linet 2015      | Occupational cohort | 73,789 benzene-exposed and      | China                          | 1972–1999          | No                   |
| [51]            |                      | 34,405 unexposed workers        |                                |                    |                      |
| McCraw 1985     | Occupational cohort | 3976 oil refinery workers       | USA: Illinois                 | 1973–1982          | No                   |
| [52]            |                      |                                |                                |                    |                      |
| Poynter 2017    | Population-based    | 420 AML cases; 265 MDS cases    | USA: Minnesota                | 2010–2014          | Yes                  |
| [53]            | case-control         | 1388 controls                   |                                |                    |                      |
| Rhomberg 2016   | Occupational cohort | 1696 Pliofilm workers           | USA: Ohio                     | 1940–1996          | No                   |
| [54]            |                      |                                |                                |                    |                      |
| Rushton 2014    | Nested case-control | 60 AML cases                    | Canada, UK, and Australia     | 1950–2006*         | No                   |
| [55]            |                      | 241 controls                    |                                |                    |                      |
| Saberi Hosnijeh | Population-based    | 241,465 adults (European        | 10 European countries:        | 1992–2010          | Yes                  |
| 2013 [33]       | cohort               | Prospective Investigation into  | Denmark, France, Greece,      |                    |                      |
|                 |                      | Cancer and Nutrition            | Germany, Italy, The            |                    |                      |
|                 |                      | cohort)                         | Netherlands, Norway, Spain,    |                    |                      |
|                 |                      |                                | Sweden, and the UK            |                    |                      |
| Sathiakumar 1995| Occupational case-  | 10 AML cases; 5 CML cases; 42   | USA                           | 1976–1990          | No                   |
| [56]            | control              | controls                        |                                |                    |                      |
| Satin 1996      | Occupational cohort | 17,844 Port Arthur oil          | USA: Texas                    | 1937–1987          | No                   |
| [57]            |                      | refinery workers                |                                |                    |                      |
| Schnatter 2012  | Occupational case-  | 29 MDS cases; 60 AML cases; 30  | Canada, UK, and Australia     | 1950–2006*         | No*                  |
| [58]            | control              | MPD cases; 28 CML cases         |                                |                    |                      |
| Stenehjem 2015  | Occupational cohort | 4 MDS cases; 10 AML cases; 3 CML cases | Norway                  | 1999–2011          | Yes                  |
| [59]            |                      | 1661 controls                   |                                |                    |                      |
| Strom 2005      | Hospital-based case- | 354 MDS cases                   | USA: Texas                    | 1999–2009          | Yes                  |
| [60]            | control              |                                |                                |                    |                      |
of the Canadian Petroleum Workers cohort reported no excess of MDS [68].

An increased mortality risk of MDS associated with 25 ppm-years or more of benzene exposure was reported, however, this finding was based on only one death [42]. A much larger registry-based study of occupational exposure to benzene and incidence of AML indicated no increased risk [34]. Age-stratified analyses indicated a possible increased risk of AML in workers under age 50 and in the highest benzene exposure group [34].

Since studies did not report results for the same subtypes of leukemia, it is problematic to combine all results using meta-analysis. We, therefore, conducted meta-analyses of results reported for myeloid leukemias combined or specifically for AML, MDS and CML (Table 6). The meta-analysis of results for AML was based on 27 estimates from 26 publications and generated a summary RR of 1.30 (95% CI 1.09–1.55; I² = 45.06%) with wide variability by exposure category (high, low, any exposure). Evidence of publication bias was present for the overall and cohort meta-analyses, but small numbers of studies hindered results for the exposure categories (Table 6). Visual inspection of funnel plots indicated that publication bias favored positive results (see supplemental file).

The meta-analysis for MDS was based on nine studies and generated a summary RR of 1.87 (95% CI 1.39–2.52; I² = 40.73%) with similar risks for the low exposure category (m-RR = 2.29, 95% CI 1.51–3.48, I² = 0%) and the high exposure category (m-RR = 1.80, 95% CI 1.18–2.75, I² = 51.97%). Publication bias appears unlikely. The meta-analyses for the overall category for each outcome were also calculated by study type (Table 6). The meta-analyses for CML by study type revealed a large difference between the case-control (m-RR = 1.93; 95% CI 1.05–3.56, I² = 25.76%) and cohort studies (m-RR = 1.13; 95% CI 0.89–1.45, I² = 0%), possibly reflecting reporting bias, as many of the case-control studies were population-based and dependent on self-reported exposure. This difference by study design was not observed for AML, MDS or the category of all myeloid leukemias combined.

The interpretation of results on risk of specific leukemia types from exposure to benzene is complicated by the heterogeneity in exposure circumstances. However, the evidence indicates a similar association between occupational exposure to benzene and specific myeloid neoplasms, but the association appears strongest for MDS, especially among more recent studies. This raises the question of whether earlier studies identifying associations between generally very high benzene exposure

| Reference | Study design | Population or Cases / controls | Study setting | Years of follow-up | Adjusted for smoking |
|-----------|--------------|---------------------------------|---------------|-------------------|---------------------|
| Talibov 2014 [34] | Population-based case-control | 14,982 AML cases, 74,505 controls | 4 Nordic countries: Finland, Norway, Sweden, and Iceland | 1960–2005 | No |
| Teras 2019 [61] | Population-based cohort | 115,996 adults (American Cancer Prevention Study-II Nutrition cohort) | USA | 1997–2013 | Yes |
| Wong 1993 [62] | Occupational cohort | 18,135 gasoline distribution workers | USA | 1946–1986 | No |
| Wong 2001a [63] | Occupational cohort | 7543 petroleum refinery workers | USA: Texas | 1945–1996 | No |
| Wong 2001b [64] | Occupational cohort | 3328 petroleum refinery workers | USA: California | 1959–1997 | No |
| Wong 2010 [65] | Hospital-based case-control | 722 AML cases, 1444 controls | China: Shanghai | 2003–2007 | No |

a Statistical model was not adjusted for smoking status, however smoking status was investigated and reported independently
b MDS and CML were not analyzed
c Study period varies by country
| Reference               | Exposure category | AML Point estimate | AML 95% CI | CML Point estimate | CML 95% CI | MDS Point estimate | MDS 95% CI | MPN Point estimate | MPN 95% CI | Myeloid leukemia Point estimate | Myeloid leukemia 95% CI |
|-------------------------|-------------------|-------------------|------------|-------------------|------------|-------------------|------------|-------------------|------------|-------------------------------|--------------------------|
| Adegoke 2003 [37]       | > 15 yrs          | 2.9               | 1.2–7.0    | 5                 | 1.8–13.9   |                   |            |                   |            |                               |                          |
| Albin 2003 [38]         | High exp          | 0.95              | 0.54–1.7   |                   |            |                   |            |                   |            |                               |                          |
| Blair 2001 [39]         | High exp.         | 1.1               | 0.3–3.9    | 0                 | –          | 2.6               | 0.7–9.7    |                   |            |                               |                          |
| Bjork 2001a [40]        | Exposed           | 1.2               | 0.66–2.3   |                   |            |                   |            |                   |            |                               |                          |
| Bonzini 2019 [41]       | 20+ years         | 2.05              | 0.66–6.36  | 1.34              | 0.17–8.80  |                   |            |                   |            | 1.98                          | 0.82–4.75                |
| Collins 2015 [42]       | 25+ ppm-yrs       | 1.39              | 0.17–5.03  |                   |            | 25.1              | 0.63–139.6 |                   |            | 1.93                          | 0.53–4.94                |
| Copley 2017 [43]        | > 12 ppm          |                   |            |                   |            | 3.47              | 1.65–7.28  |                   |            |                               |                          |
| Costantini 2008 [44]    | M/H exp           | 0.9               | 0.4–2.3    |                   |            |                   |            |                   |            |                               |                          |
| Divine 1999 [45]        | Exposed           | 1.29              | 0.79–1.99  | 1.05              | 0.54–1.83  |                   |            |                   |            |                               |                          |
| Divine 2000 [46]        | Exposed           | 1.92              | 1.10–3.13  | 0.94              | 0.34–2.05  |                   |            |                   |            |                               |                          |
| Guenel 2002 [47]        | > 5.5 unit-yrs    | 2.4               | 0.7–8.5    | 1.2               | 0.1–11.4   |                   |            |                   |            |                               |                          |
| Huebner 2009 [48]       | Exposed           | 1.07              | 0.84–1.36  | 1.01              | 0.67–1.47  | 1.64              | 0.78–3.01  |                   |            |                               |                          |
| Ireland 1997† [49]      | ≥ 72 ppm-mo       | 4.5               | 0.1–25.3   |                   |            |                   |            |                   |            |                               |                          |
| Kirkeleit 2008 [50]     | Exposed           | 2.89              | 1.25–6.67  | 1.44              | 0.19–10.7  |                   |            |                   |            |                               |                          |
| Linet 2015 [51]         | Exposed           | 2.1               | 0.9–5.2    | 2.5               | 0.8–10.7   |              1.9–∞ | 2.2         | 1.1–4.6 |                               |                          |
| McCraw 1985 [52]        | Exposed           | 3.94              | 1.72–7.88  | 1.21              | 0.02–6.96  |                   |            |                   |            |                               |                          |
| Poynter 2017 [53]       | ≥ 5 years         | 1.77              | 1.19–2.63  | 2.10              | 1.35–3.28  |                   |            |                   |            |                               |                          |
| Rhomberg 2016 [54]      | ≥ (80.11 ppm-yrs) | 10.11             | 3.71–22.01 |                   |            |                   |            |                   |            |                               |                          |
|                        | (0 lag)           |                   |            |                   |            |                   |            |                   |            |                               |                          |
|                        | ≥ 74.55 ppm-yrs   | 10.76             | 3.95–23.43 |                   |            |                   |            |                   |            |                               |                          |
|                        | (10 yr lag)       |                   |            |                   |            |                   |            |                   |            |                               |                          |
|                        | ≥ 73.53 ppm-yrs   | 6.37              | 1.31–18.61 |                   |            |                   |            |                   |            |                               |                          |
|                        | (20 yr lag)       |                   |            |                   |            |                   |            |                   |            |                               |                          |
| Rushton 2014 [55]       | > 2.93 ppm-yrs    | 1.39              | 0.68–2.85  |                   |            |                   |            |                   |            |                               |                          |
|                        | > 0.259 ppm       | 1.90              | 0.86–4.18  |                   |            |                   |            |                   |            |                               |                          |
|                        | > 28 yrs          | 1.70              | 0.75–3.87  |                   |            |                   |            |                   |            |                               |                          |
|                        | > 0.413 max ppm   | 1.65              | 0.75–3.63  |                   |            |                   |            |                   |            |                               |                          |
| Saberi Hosnijeh 2013 [33]| Exposed          | 1.52              | 0.78–1.81  | 1.97              | 0.75–5.19  |                   |            |                   |            | 1.60                          | 0.95–2.69                |
| Sathiakumar 1995 [56]   | Exposed           | 2.8               | 1.1–7.3    | 1.6               | 0.43–5.9   |                   |            |                   |            | 2.1                           | 1.0–4.3                 |
| Satin 1996 [57]         | Exposed           | 0.63              | 0.30–1.15  | 0.84              | 0.31–1.84  |                   |            |                   |            |                               |                          |
| Schnatter 2012 [58]     | > 2.98 ppm-yrs    | 2.20              | 0.63–7.68  | 4.33              | 1.31–14.3  | 1.79              | 0.68–4.74  |                   |            |                               |                          |
|                        | > 0.259 ppm       | 0.91              | 0.25–3.28  | 3.12              | 0.90–10.8  | 1.17              | 0.39–3.52  |                   |            |                               |                          |
| Reference          | Exposure category | AML | CML | MDS | MPN | Myeloid leukemia |
|--------------------|-------------------|-----|-----|-----|-----|------------------|
|                    |                   | Point estimate | 95% CI | Point estimate | 95% CI | Point estimate | 95% CI | Point estimate | 95% CI | Point estimate | 95% CI |
|                    | > 28 yrs          | 1.42 | 0.35–5.67 | 1.74 | 0.61–4.99 | 0.82 | 0.25–2.73 |
|                    | > 0.413 max ppm   | 0.59 | 0.15–2.37 | 2.81 | 0.79–10.1 | 0.85 | 0.28–2.61 |
| Stenehjem 2015 [59]| ≥ 0.124 ppm-yrs  | 4.85 | 0.88–27.0 | 2.24 | 0.65–7.71 |
|                    | ≥13 yrs           | 0.97 | 0.08–11.0 | 1.47 | 0.37–5.88 |
|                    | > 0.013 ppm       | 3.47 | 0.63–19.0 | 1.66 | 0.48–5.74 |
| Strom 2005 [60]    | High exp          | 2.05 | 1.20–3.51 |
| Talibov 2014 [34]  | > 136 ppm-yrs     | 0.80 | 0.56–1.15 |
| Teras 2019 [61]    | ≥1.49 μg/m³       | 0.98 | 0.68–1.42 | 0.89 | 0.67–1.19 |
| Wong 1993 [62]     | Exposed (marine)  | 0.74 | 0.24–1.73 | 1.33 | 0.36–3.4 |
|                    | Exposed (land)    | 1.51 | 0.80–2.57 | 0.26 | 0.01–1.43 |
| Wong 2000a [63]    | Exposed           | 1.47 | 0.76–2.57 | 1.31 | 0.43–3.07 |
| Wong 2001b [64]    | Exposed           | 0.45 | 0.01–2.53 | 1.96 | 0.24–7.07 |
| Wong 2010 [65]     | Exposed           | 1.43 | 1.05–1.93 |

* Only studies reporting results on specific myeloid malignancy types are reported. †Study reports acute-nonlymphocytic leukemia (ANLL). ‡RR estimate is for MDS/AML combined. §Myeloid malignancies including MDS. Four cases of MDS were reported, and MDS was not analyzed separately. 

**Abbreviations:** NA Not available; M/H Medium/High; exp. Exposure; mo Months; ppm Parts per million; yrs. Years;
and AML might have reflected the occurrence of secondary AML following unrecognized (or misdiagnosed) primary cases of MDS. It is noteworthy that a very large record linkage study from the Nordic countries reported no association between benzene exposure and AML incidence [34].

Tobacco smoking

The IARC last evaluated the carcinogenicity of tobacco smoking in 2009 [69]. From the IARC review and the PubMed search, we identified 42 studies on tobacco smoking and risk of myeloid malignancies, 27 of which reported results for current or ever smokers (current and former smokers combined) as summarized in Table 7. The remaining studies reported results for different groups of smokers, defined according to dose (cigarettes per day), duration (years of smoking) or cumulative consumption (pack-years). Whenever possible, we selected results by duration of smoking, since this is the exposure metric most strongly associated with lung cancer risk (Table 8).

One of the largest studies to examine leukemia risks among smokers was a prospective cohort of 1.3 million middle-aged women recruited for breast cancer screening during 1996–2001 and followed for mortality through 2009 [84]. The investigators identified

---

Table 6 Meta-analyses of studies of specific myeloid malignancy type for benzene.*

| Characteristics | No. of estimates | Meta-RR estimate (95%CI) | I² test (%) | p-value | Egger’s test |
|-----------------|------------------|--------------------------|-------------|---------|--------------|
| ML Overall      | 7                | 1.56 (1.10–2.20)         | 45.06       | 0.0114  | 0.0063**     |
| High exposure   | 4                | 1.28 (0.87–1.88)         | 40.98       | 0.2051  | 0.0984       |
| Low exposure    | 1                | 2.24 (0.65–7.71)         | NA          | 0.2012  | NA           |
| Any exposure    | 2                | 2.15 (1.29–3.58)         | 0.00        | 0.0033  | NA           |
| Study type      |                  |                          |             |         |              |
| Case-control studies | 0       |                          |             |         |              |
| Cohort studies  | 7                | 1.56 (1.10–2.20)         | 45.06       | 0.0114  | 0.0063**     |
| AML Overall     | 27               | 1.30 (1.09–1.55)         | 48.91       | 0.0037  | 0.0155**     |
| High exposure   | 8                | 1.65 (1.13–2.41)         | 46.97       | 0.0100  | 0.1176       |
| Low exposure    | 5                | 1.54 (0.89–2.66)         | 58.71       | 0.1248  | 0.2679       |
| Any exposure    | 14               | 1.14 (0.93–1.39)         | 36.29       | 0.2057  | 0.3933       |
| Study type      |                  |                          |             |         |              |
| Case-control studies | 9       | 1.34 (1.03–1.75)         | 40.12       | 0.0281  | 0.5929       |
| Cohort studies  | 18               | 1.29 (1.02–1.63)         | 51.98       | 0.0364  | 0.0119**     |
| CML Overall     | 18               | 1.25 (1.00–1.55)         | 0.00        | 0.0456  | 0.2347       |
| High exposure   | 3                | 2.79 (1.44–5.40)         | 0.00        | 0.0024  | 0.7110       |
| Low exposure    | 2                | 1.93 (0.64–5.82)         | 0.00        | 0.2447  | NA           |
| Any exposure    | 13               | 1.11 (0.87–1.40)         | 0.00        | 0.4019  | 0.4132       |
| Study type      |                  |                          |             |         |              |
| Case-control studies | 5       | 1.93 (1.05–3.56)         | 25.76       | 0.0353  | 0.6999       |
| Cohort studies  | 13               | 1.13 (0.89–1.45)         | 0.00        | 0.3215  | 0.3540       |
| MDS Overall     | 9                | 1.87 (1.39–2.52)         | 40.73       | < 0.0001| 0.0560       |
| High exposure   | 6                | 1.80 (1.18–2.75)         | 51.97       | 0.0065  | 0.1173       |
| Low exposure    | 2                | 2.29 (1.51–3.48)         | 0.00        | < 0.0001| NA           |
| Any exposure    | 1                | 1.64 (0.83–3.22)         | N/A         | 0.1510  | NA           |
| Study type      |                  |                          |             |         |              |
| Case-control studies | 5       | 1.85 (1.28–2.67)         | 33.43       | 0.0012  | 0.5538       |
| Cohort studies  | 4                | 1.94 (1.19–3.18)         | 43.78       | 0.0081  | 0.1088       |

*MPN not included as only one published point estimate was identified.**Statistically significant (p < 0.05)
| Reference     | Study design                                      | Population (cohort) | Study setting | Study period     |
|---------------|--------------------------------------------------|---------------------|---------------|------------------|
| Avgirinou 2017 [70] | Hospital-based case-control                       | 126 MDS cases 102 controls | Greece        | 2009–2013        |
| Batty 2008 [71]   | Occupational cohort                               | 17,322 government workers | London        | 1967–2005        |
| Bjork 2000 [72]   | Population-based case-control                     | 330 MDS cases 337 controls | Southern Sweden | 1976–1993        |
| Bjork 2001b [73]  | Population-based case-control                     | 284 AML cases 332 controls | Southern Sweden | 1976–1993        |
| Bjork 2009 [74]   | Population- and hospital-based case-control       | 79 MDS cases; 104 AML cases 278 controls | Southern Sweden | 2001–2004        |
| Brown 1992 [75]   | Population-based case-control                     | 178 AML cases; 65 CML cases 1742 controls | Iowa and Minnesota | 1981–1984        |
| Brownson 1991 [76] | Registry-based case-control                       | M: 189 AML cases; 88 CML cases 1899 controls  F: 178 AML cases; 65 CML cases 1742 controls | Missouri | 1984–1990        |
| Dalamaga 2002 [77] | Hospital-based case-control                       | 84 MDS cases 84 controls | Greece        | 1995–2000        |
| Fernberg 2007 [78] | Occupational cohort                               | 336,381 construction workers | Sweden        | 1969–2004        |
| Ido 1996 [79]     | Hospital-based case-control                       | 116 MDS cases 116 controls | Japan        | Sep-Oct 1992 and Aug-Oct 1993 |
| Kabat 1988 [80]   | Hospital-based case-control                       | 249 ANLL cases; 78 CML cases 9342 non-cancer controls | USA: Nine cities | 1969–1985        |
| Kabat 2013 [81]   | Population-based cohort                           | 493,188 adults aged 50–71 years at entry (NIH- AARP Diet and Health Study) | USA | 1995–2006        |
| Kane 1999 [82]    | Population-based case-control                     | 695 AML cases 1374 controls | England       | 1991–1996        |
| Kasim 2005 [83]   | Population-based case-control                     | 307 AML cases; 169 CML cases 5039 controls | Canada        | 1994–1997        |
| Kroll 2012 [84]   | Population-based cohort                           | 1.3 million middle-aged women (UK Million Women cohort) | UK | 1996–2009        |
| Leal 2014 [85]    | Population-based cohort                           | 27,370 women aged 55–69 yrs. at entry (Iowa Women’s Health Study cohort) | USA: Iowa | 1993–2004        |
| Linet 1991 [86]   | Population-based cohort                           | 17,633 members of Lutheran Brotherhood | USA | 1966–1986        |
| Lv, 2011 [87]     | Hospital-based case-control                       | 403 MDS cases, 806 controls | China: Shanghai | 2003–2006        |
| Ma 2009, 2010 [88, 89] | Population-based cohort study                   | 471,799 adults aged 50–71 years at entry (NIH AARP Diet and Health Study) | USA | 1995–2003        |
| Mele 1994 [90]    | Hospital based case-control                       | 55 MDS cases; 118 AML cases; 78 CML cases 467 controls | Italy | 1986–1990        |
| Mills 1990 [91]   | Population-based cohort                           | 34,000 Seventh Day Adventists | USA | 1974–1982        |
| Musselman 2013 [92] | Population-based case-control                     | 413 AML cases; 184 CML cases 1022 controls | USA: Minnesota | 2005–2009        |
| Nagata 1999 [93]  | Population-based case-control                     | 111 MDS cases 830 controls | Japan        | 1995–1996        |
| Nisse 2001 [94]   | Population-based case-control                     | 204 MDS cases 204 controls | Northern France | 1991–1996        |
| Parodi 2017 [95]  | Population-based case-control                     | 223 AML cases; 106 CML cases 1774 controls | Italy | 1990–1993        |
| Pasqualetti 1997 [96] | Hospital-based case-control                       | 73 ANNL cases; 85 MDS cases; 92 MPN cases | Italy | circa 1971–1996 |
death due to myeloid neoplasm in 831 cohort members and reported a statistically significantly increased risk (RR = 1.33, 95% CI 1.24–1.42). The increase was driven by a significant RR for MPN/MDS (RR = 1.42, 95% CI 1.31–1.55), whereas the RR for AML was not elevated (RR = 1.10, 95% CI 0.96–1.26). Relative risks also increased with increased intensity of smoking for myeloproliferative/myelodysplastic disease, but not for AML [84].

A cohort study of over 330,000 Swedish construction workers with follow-up for mortality through 2004 reported a statistically significant association between “current” smoking and AML risk (RR = 1.50, 95% CI: 1.06, 2.11), but no association with CML (RR = 0.69, 95% CI 0.42–1.14). For AML, relative risks did not increase with increasing intensity of smoking [78].

Table 9 presents summary risk estimates for myeloid malignancies by various smoking exposure metrics and study type. Several meta-analyses demonstrated significant heterogeneity, as indicated by the high I² statistic and associated low p-values. However, publication bias generally was not indicated.

The meta-analysis for smoking and AML was based on 28 studies and resulted in a summary RR of 1.43 (95% CI 1.25–1.62; I² = 56.25%) with slightly higher meta-RR for current smokers and a lower meta-RR for ever smokers. Meta-analysis of results for CML was based on 14 studies, generating a summary RR of 0.93 (95% CI 0.74–1.16; I² = 40.44%) with similar results for current and ever smokers. The meta-RR for myeloid leukemias combined (i.e., based on eight studies not differentiating by leukemia type) was 1.54 (95% CI 0.79–3.01; I² =

### Table 7: Select characteristics of tobacco smoking studies (Continued)

| Reference       | Study design          | Population (cohort) Cases/controls     | Study setting         | Study period     |
|-----------------|-----------------------|----------------------------------------|-----------------------|-----------------|
| Pedersen 2018 [97] | Population-based cohort study | (includes 69 with CML) 75, 896 adults in Denmark (Danish Health Examination Survey) 160 controls | Denmark | 2007–2015 |
| Pekmezovic 2006 [98] | Hospital-based case-control | 80 MDS cases 160 controls | Serbia Montenegro | 2000–2003 |
| Pogoda 2002 [99] | Population-based case-control | 412 AML cases 412 controls | USA; Los Angeles | 1987–1994 |
| Richardson 2008 [100] | Population-based case-control | 120 ANLL cases; 69 CML cases 423 controls | Germany | 1986–1998 |
| Sandler 1993 [101] | Population-based case-control | 15 MDS cases; 423 AML cases 618 Controls | USA and Canada | 1986–1989 |
| Severson 1990 [102] | Population-based case-control | 106 AML cases (93 AML) 128 controls | USA: Seattle | 1984–1986 |
| Speer 2002 [103] | Registry-based case-control | 604 AML cases 7112 controls (colon cancer patients) | USA: Orange County, California | 1984–1993 |
| Stagnaro 2001 [104] | Population-based case-control | 105 AML cases; 105 CML cases 1765 controls | Italy | 1990–1993 |
| Strom 2005 [60] | Hospital-based case-control | 354 MDS cases 452 controls | Texas | 1999–2003 |
| Strom 2012 [105] | Population-based case-control | 638 AML cases 636 controls | Texas | 2003–2007 |
| Ugai 2017a,2017b [106, 107] | Population-based cohort | 96,992 members of Japan Public Health Center-Based Prospective Study | Japan | 1990–2012 |
| Wakabayashi 1994 [108] | Hospital-based case-control | 75 ANNL cases 150 controls | Japan | 1981–1988 |
| West 1995 [109] | Population-based case-control | 400 MDS cases 400 controls | England and Wales | Not reported |
| Wong 2009 [110] | Hospital-based case-control study | 722 AML cases 144 controls | China/Shanghai | 2003–2007 |
| Xu 2007 [111] | Population-based cohort | 24,539 members of Three Mile Island cohort | USA; Pennsylvania | 1979–1995 |
| Exposure                  | MDS                      | AML                      | CML                      | MPN                      | Myeloid l. |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------|
|                          | Point estimate | 95% CI   | Point estimate | 95% CI   | Point estimate | 95% CI   | Point estimate | 95% CI   | Point estimate | 95% CI |
| Averginou 2017 [70]     | CS 0.94          | 0.46–191        | ES 1.18          | 0.69–202        |               |           |               |           |               |        |
| Batty 2008 [71]         | CS               |            |               |            |               |           |               |           |               |        |
|                          | 10 cpd_c 2.0      | 1.3–3.1         | 10 yr_c 3.5     | 1.9–64          |               |           |               |           |               |        |
| Bjork 2000 [72]         | Recent smokers 2.0  | 1.3–3.1         | > 10 cpd, > 40 yrs 3.5 | 1.9–64          |               |           |               |           |               |        |
|                          | > 40 yrs 3.0      | 1.6–58          |               |            |               |           |               |           |               |        |
| Bjork 2001b [73]        | > 10 cpd, > 20 yrs 1.6 | 1.0–2.4         |               |            |               |           |               |           |               |        |
| Bjork 2009 [74]         | CS smoker 1.2     | 0.70–22         | ≥20 yrs 1.4     | 0.78–25          |               |           |               |           |               |        |
|                          | ≥20 pyrs 1.6      | 0.85–3.1        |               |            |               |           |               |           |               |        |
| Brown 1992 [75]         | CS 1.7           | 0.9–2.9         | > 20 cpd 1.3    | 0.7–2.4          |               |           |               |           |               |        |
|                          | ≥46 yrs 1.5       | 0.8–2.8         |               |            |               |           |               |           |               |        |
| Brownson 1991 [76]      | ≥20 cpd, males 1.2 | 0.7–1.9         | ≥20 cpd, females 1.4 | 0.8–2.2          |               |           |               |           |               |        |
| Dalamaga 2002 [77]      | CS (non-drinker) 1.73 | 0.58–5.18       |               |            |               |           |               |           |               |        |
| Fernberg 2007 [78]      | CS 1.50          | 1.06–2.11       |               |            |               |           |               |           |               |        |
|                          | > 20 cpd 1.59     | 0.9–2.79        |               |            |               |           |               |           |               |        |
| Ido 1996 [79]           | ES 1.8           | 0.83–3.89       |               |            |               |           |               |           |               |        |
| Kabat 1988 [80]         | ES 0.83          | 0.61–1.14       | ≥31 cpd 0.71   | 0.37–1.37        |               |           |               |           |               |        |
| Kabat 2013 [81]         | ≥21 cpd 1.53     | 1.03–2.27       |               |            |               |           |               |           |               |        |
| Kane 1999 [82]          | CS 1.4           | 1.1–1.8         | 40+ yrs 1.3    | 0.9–1.9         |               |           |               |           |               |        |
| Kasim 2005 [83]         | CS 1.4           | 1.1–1.8         |               |            |               |           |               |           |               |        |
|                          | > 20 yrs 1.5      | 1.1–2.0         |               |            |               |           |               |           |               |        |
| Kroll 2012 [84]         | ≥15 cpd 1.98     | 1.67–2.35       | 108 0.80–1.46 |               |               | 1.69      | 1.46–1.96     |            |               |        |
| Leal, 2014 [85]         | CS 1.61          | 1.06–2.45       |               |            |               | 08        | 03–1.8        |            |               |        |
| Linet 1991 [86]         | ES               |               |               |            |               |           |               |           |               |        |
### Table 8 Results of studies on tobacco smoking and specific type of myeloid malignancies (Continued)

| Exposure | MDS | AML | CML | MPN | Myeloid l. |
|----------|-----|-----|-----|-----|------------|
|          | Point estimate | 95% CI | Point estimate | 95% CI | Point estimate | 95% CI | Point estimate | 95% CI | 95% CI |
| 20+ cpd  |  | 1.37 | 0.89–2.12 |  |  |  |  |  | 13 | 0.5–3.8 |
| Lv 2011 [87] | CS | 1.72 | 0.91–1.63 | 4.06 | 2.29–7.13 | 4.06 | 2.29–7.13 |  |  |  |
| >20 yrs | 1.06 | 0.75–1.50 | 1.06 | 0.73–1.55 |  |  |  |  |  |  |
| >20 cpd | 1.06 | 0.73–1.55 |  |  |  |  |  |  |  |  |
| >20 yrs | 1.06 | 0.73–1.55 |  |  |  |  |  |  |  |  |
| Ma 2009; 2010 [88, 89] | CS | 3.17 | 2.02–4.98 | NR | NR |  |  |  |  |  |
| > 25 yrs | 2.4 | 1.0–5.8 | 1.7 | 0.9–3.0 | 1.0 | 0.5–2.1 |  |  |  |
| > 20 yrs | 1.2 | 0.4–3.3 | 1.6 | 0.9–2.8 | 1.3 | 0.7–2.6 |  |  |  |
| Mele 1994 [90] | CS | 3.17 | 2.02–4.98 | NR | NR |  |  |  |  |  |
| > 25 cpd | 2.4 | 1.0–5.8 | 1.7 | 0.9–3.0 | 1.0 | 0.5–2.1 |  |  |  |
| > 20 yrs | 1.2 | 0.4–3.3 | 1.6 | 0.9–2.8 | 1.3 | 0.7–2.6 |  |  |  |
| Mills 1990 [91] | CS | 3.17 | 2.02–4.98 | NR | NR |  |  |  |  |  |
| > 25 cpd | 2.4 | 1.0–5.8 | 1.7 | 0.9–3.0 | 1.0 | 0.5–2.1 |  |  |  |
| > 20 yrs | 1.2 | 0.4–3.3 | 1.6 | 0.9–2.8 | 1.3 | 0.7–2.6 |  |  |  |
| Nisse 2001 [94] | CS/Ex-S | 3.4 | 1.7–7.3 |  |  |  |  |  |  |  |
| ≥20 pyrs | 2.6 | 1.1–6.8 |  |  |  |  |  |  |  |  |
| Parodi 2017 [95] | CS | 0.43 | 0.23–0.82 | 0.81 | 0.35–1.19 | 0.52 | 0.31–0.88 |  |  |  |
| Pasqualetti 1997 [96] | Heavy smokers | 3.00 | 1.09–8.25 | 3.20 | 1.17–8.73 | 1.25 | 0.59–2.67 |  |  |  |
| Pedersen 2018 [97] | Daily smokers | 3.00 | 1.09–8.25 | 3.20 | 1.17–8.73 | 1.25 | 0.59–2.67 |  |  |  |
| Pekmezovic 2006 [98] | > 25 yrs | 1.0 | 0.4–2.3 |  |  |  |  |  |  |  |
| > 20 cpd | 1.3 | 0.4–3.6 |  |  |  |  |  |  |  |  |
| Pogoda 2002 [99] | ES | 12 | 0.9–1.6 |  |  |  |  |  |  |  |
| > 35 yrs | 2.9 | 1.1–7.2 |  |  |  |  |  |  |  |  |
| > 20 cpd | 3.4 | 1.4–8.2 |  |  |  |  |  |  |  |  |
| > 40 pyrs | 2.3 | 0.9–5.6 |  |  |  |  |  |  |  |  |
| Richardson 2008 [100] | CS | 1.04 | 0.47–2.30 |  |  |  |  |  |  |  |
| 10 pys_c | 1.07 | 0.97–1.17 |  |  |  |  |  |  |  |  |
| Sandler 1993 [101] | ES | 1.64 | 0.53–5.07 | 1.18 | 0.91–1.54 |  |  |  |  |  |
| > 40 pyrs | 142 | 1.00–2.07 |  |  |  |  |  |  |  |  |
| Exposure          | MDS  |   |   | AML  |   |   | CML  |   |   | MPN  |   |   | Myeloid l. |   |   |
|-------------------|------|---|---|------|---|---|------|---|---|------|---|---|------------|---|---|
|                    | Point estimate | 95% CI |   | Point estimate | 95% CI |   | Point estimate | 95% CI |   | Point estimate | 95% CI |   |
| Severson 1990 [102] | ES   | 2.1 | 1.2–3.9 |   |   |   |   |   |   |   |   |   |
|                   | CS   | 1.9 | 0.9–3.7 |   |   |   |   |   |   |   |   |   |
|                   | ≥40 pyrs | 3.1 | 1.4–7.4 |   |   |   |   |   |   |   |   |   |
| Speer 2002 [103]   | CS   | 2.2 | 1.6–3.0 |   |   |   |   |   |   |   |   |   |
| Stagnaro 2001 [104] | CS  | 0.93 | 0.61–1.4 | 0.59 | 0.34–1.0 |   |   |   |   |   |   |
|                   | ≥20 cpd | 1.2 | 0.74–1.9 | 0.45 | 0.23–0.87 |   |   |   |   |   |   |
|                   | ≥37 yrs | 1.2 | 0.72–1.9 | 0.56 | 0.30–1.1 |   |   |   |   |   |   |
| Strom 2005 [60]    | ES   | 1.65 | 1.19–2.30 |   |   |   |   |   |   |   |   |   |
|                   | Per py | 1.01 | 1.00–1.02 |   |   |   |   |   |   |   |   |   |
| Strom 2012 [105]   | > 30 pyrs, women | 1.34 | 0.72–2.50 |   |   |   |   |   |   |   |   |   |
|                   | > 30 pyrs, men | 1.86 | 1.15–3.02 |   |   |   |   |   |   |   |   |   |
| Uga 2017a [106]    | > 30 pys/CS | 2.02 | 1.00–4.06 | 1.19 | 0.36–3.91 |   |   |   |   |   |   |
| Uga 2017b [107]    | CS   | 1.62 | 0.80–3.27 |   |   |   |   |   |   |   |   |   |
|                   | > 30 yrs | 1.74 | 0.84–3.59 |   |   |   |   |   |   |   |   |   |
| Wakabayashi 1994 [108] | ≥31 cpd | 2.99 | 0.66–13.47 |   |   |   |   |   |   |   |   |   |
| West 1995 [109]    | ES   | 1.16 | 0.83–1.63 |   |   |   |   |   |   |   |   |   |
|                   | ≥25 cpd | 1.0 | (NR) |   |   |   |   |   |   |   |   |   |
| Wong 2009 [110]    | > 20 cpd | 0.96 | 0.58–1.57 |   |   |   |   |   |   |   |   |   |
|                   | > 20 yrs | 1.33 | 0.99–1.77 |   |   |   |   |   |   |   |   |   |
|                   | > 20 pyrs | 1.29 | 0.95–1.75 |   |   |   |   |   |   |   |   |   |
| Xu 2007 [111]      | CS   | 3.47 | 1.00–12.0 |   |   |   |   |   |   |   |   |   |
|                   | > 20 cpd | 1.07 | 0.23–5.01 |   |   |   |   |   |   |   |   |   |
|                   | > 30 yrs | 3.64 | 0.80–16.5 |   |   |   |   |   |   |   |   |   |
|                   | > 20 pyrs | 1.11 | 0.19–6.36 |   |   |   |   |   |   |   |   |   |

*a results for FAB subtype M2, 107 cases/107 controls

Abbreviations: CS Current smoker; cpd Cigarettes per day; ES Ever smoked (combined current and former smokers); pys Pack-years; RR Relative risk; yrs Years of smoking.
Table 9 Meta-analyses of studies specific leukemia types for smoking

| Characteristics | No. of estimates | Meta-RR estimate (95%CI) | $I^2$ test (%) | p-value | Egger's test |
|-----------------|------------------|--------------------------|----------------|---------|--------------|
| ML              |                  |                          |                |         |              |
| Overall         | 6                | 1.54 (0.79–3.01)         | 81.80          | 0.2038  | 0.8539       |
| Smoking status  |                  |                          |                |         |              |
| Current smoker  | 3                | 1.55 (0.44–5.46)         | 75.24          | 0.4942  | 0.4930       |
| Ever smoker     | 3                | 1.68 (1.45–1.94)         | 0.00           | <0.0001 | 0.9406       |
| Study type      |                  |                          |                |         |              |
| Case-control studies | 1  | 0.52 (0.31–0.88)   | 0.00           | <0.0001 | NA           |
| Cohort studies  | 5                | 1.71 (1.49–1.98)         | 0.00           | <0.0001 | 0.5972       |
| AML             |                  |                          |                |         |              |
| Overall         | 28               | 1.43 (1.25–1.62)         | 56.25          | <0.0001 | 0.0848       |
| Smoking status  |                  |                          |                |         |              |
| Current smoker  | 21               | 1.49 (1.28–1.72)         | 53.64          | <0.0001 | 0.3747       |
| Ever smoker     | 7                | 1.22 (1.00–1.48)         | 34.43          | 0.00497 | 0.1008       |
| Study type      |                  |                          |                |         |              |
| Case-control studies | 23  | 1.43 (1.26–1.63)   | 46.25          | <0.0001 | 0.3784       |
| Cohort studies  | 5                | 1.43 (1.03–1.99)         | 69.14          | 0.0351  | 0.0882       |
| CML             |                  |                          |                |         |              |
| Overall         | 14               | 0.93 (0.74–1.16)         | 40.44          | 0.5242  | 0.7871       |
| Smoking status  |                  |                          |                |         |              |
| Current smoker  | 8                | 0.81 (0.64–1.01)         | 0.00           | 0.0637  | 0.0347       |
| Ever smoker     | 6                | 1.05 (0.71–1.56)         | 56.51          | 0.8101  | 0.6791       |
| Study type      |                  |                          |                |         |              |
| Case-control studies | 11  | 0.88 (0.69–1.11)   | 25.34          | 0.2641  | 0.1266       |
| Cohort studies  | 3                | 1.08 (0.67–1.74)         | 48.86          | 0.7513  | 0.0857       |
| MDS             |                  |                          |                |         |              |
| Overall         | 22               | 1.66 (1.38–2.00)         | 61.89          | <0.0001 | 0.7014       |
| Smoking status  |                  |                          |                |         |              |
| Current smoker  | 13               | 1.69 (1.28–2.22)         | 62.94          | 0.0002  | 0.9380       |
| Ever smoker     | 7                | 1.51 (1.21–1.87)         | 44.07          | 0.0002  | 0.1445       |
| Study type      |                  |                          |                |         |              |
| Case-control studies | 18  | 1.42 (1.25–1.62)   | 2.32           | <0.0001 | 0.3969       |
| Cohort studies  | 4                | 2.58 (1.80–3.70)         | 63.99          | <0.0001 | 0.4004       |
| MPN             |                  |                          |                |         |              |
| Overall         | 3                | 1.70 (1.23–2.34)         | 0.00           | 0.0013  | 0.9210       |
| Smoking status  |                  |                          |                |         |              |
| Current smoker  | 3                | 1.70 (1.23–2.34)         | 0.00           | 0.0013  | 0.9210       |
| Ever smoker     | 0                |                          |                | NA      |              |
| Study type      |                  |                          |                |         |              |
| Case-control studies | 1  | 1.25 (0.59–2.66)   | 0.00           | 0.5623  | NA           |
| Cohort studies  | 2                | 1.82 (1.27–2.59)         | 0.00           | 0.0011  | NA           |

*a statistically significant

81.80%) with similar results for current and ever smokers. The meta-analysis of overall results on MDS was based on 22 studies and resulted in a summary RR of 1.66 (95% CI 1.38–2.00; $I^2 = 61.89\%$) with similar results for current and ever smokers. Only three studies were identified for MPN resulting
in a summary RR of 1.70 (95% CI 1.23–2.34; I² = 0%) for current smokers. Publication bias appears unlikely for the meta-analyses on smoking except for the Egger’s test results for the category of current smoker and CML. Visual inspection of the funnel plot, however, did not suggest any publication bias (see supplemental file).

In contrast to benzene, the evidence on the risk of specific leukemia subtypes from tobacco smoking indicates an association with AML, but not with CML. Similar to benzene, there is evidence of an increased risk of MDS. Although only three studies were identified, risk of myeloproliferative/myelodysplastic neoplasm (MPN) appears to be increased among smokers.

Discussion

The myeloid malignancies clearly have different clinical features and characteristic genetic aberrations and therefore, they should be evaluated separately in epidemiological studies intended to identify risk factors and potential causes.

We found little consistency in the way leukemias were evaluated, and they often were analyzed in aggregate, mixing myeloid and lymphocytic leukemias. The more recent benzene cohort studies were the exception, as they specifically evaluated AML, CML and MDS separately. Some analyses evaluated myeloid malignancies separately from the lymphocytic neoplasms, but still combined AML and CML, despite evidence of different mutations in genes and other risk factors that indicate different etiologies. Despite the determination that the epidemiological evidence was sufficient for purposes of establishing causation for leukemia, our review identified only small numbers of studies that actually reported results for specific types of myeloid neoplasms. Furthermore, where specific diseases were considered, small numbers of observed events often limited the precision of risk estimates.

For example, for butadiene, only one study analyzed risks by specific leukemia type, and findings were mixed: statistically significant associations were reported for CML among laboratory workers (based on only three deaths) but not for AML [25]. That results on butadiene exposure and myeloid malignancies are based on a single study and do not allow any causal conclusions does not necessarily mean that the IARC conclusion of “sufficient” human evidence is incorrect. Rather, it indicates that the relationship, if any, with one or more specific type of leukemia cannot be discerned based on available epidemiological evidence.

The updated meta-RRs for formaldehyde showed no consistent relationship with AML, CML or myeloid leukemia overall, confirming an earlier meta-analysis [28]. A further meta-analysis of the highest exposure groups was not conducted due to a lack of a common exposure metric. A very large registry-based linkage study demonstrated no increased risk and, in fact, reported a statistically significant deficit of incident AML cases among groups potentially occupationally exposed to formaldehyde [34]. Our findings suggest that the updated human evidence for formaldehyde and leukemia (of any type) may not be sufficient as determined by IARC and should be revisited. Combined with the lack of support from animal and mechanistic studies, it is unlikely that formaldehyde causes leukemia in humans [112].

A causal relationship between benzene exposure and AML has been recognized for decades and our meta-analyses indicate a significant increased risk overall and at high levels of exposure, yet the largest study, the Nordic registry study, demonstrated no association [34]. Other recent high-quality studies also indicate no clear association between benzene and AML risk [33, 42, 48, 55], possibly due to generally low exposure concentrations that do not exceed a possible exposure threshold for risk. The most comprehensive study on benzene and incident leukemia and myeloid neoplasm risks demonstrated a stronger association between benzene and risk of MDS than for AML, especially among workers with high peak exposures [58]. However, subsequent analyses of the Canadian sub-cohort were not consistent with these findings [68]. An association was reported between benzene and CML, but this was limited to case-control studies and may reflect potential reporting bias. Nevertheless, these findings epidemiologically underscore the importance of examining and contrasting results for specific malignancies (at least initially) and that exposure metric may play an important role in identifying causal associations [27].

Findings for tobacco smoking and myeloid leukemia were consistently positive for AML and negative for CML. The meta-RR for AML demonstrated a 50% statistically significantly increased risk, whether based on seven studies reporting individual leukemia types or the six in which AML and CML were reported separately. These results, and specifically the statistically significant positive meta-RR for AML and null findings for CML, further underscore the importance of examining epidemiologically narrowly defined or disease-specific relationships.

An ancillary finding of this evaluation is the surprisingly limited body of epidemiological studies aimed at addressing and differentiating risks by specific types of myeloid malignancy. While observing small numbers of any specific leukemia will plague all but the largest studies (or studies in which a strong association is indicated), we would argue that arbitrarily combining possibly
discrete disease entities to improve “statistical power” will not help elucidate their specific causes; rather, this technique likely will dilute any true malignancy-specific associations and may lead to erroneous conclusions. One exception might be the subset of MDS cases that progresses to AML: these may reflect different clinical stages in the progression of the same disease. Nevertheless, publishing results based on small numbers will facilitate combining results across studies using meta-analysis. It is conceivable that apparently negative findings based on small numbers may not be published, leading to potential “small numbers” or “negative study” publication bias, of which we found some evidence. While concerns of uncontrolled confounding arise in many occupational epidemiological settings, it is unlikely to be problematic in this context, primarily because there are no common exposures or risk factors that are strongly associated with all (or even multiple) types of leukemia. Progress in understanding the genetic factors underlying each of the myeloid neoplasms likely will guide future epidemiological studies to improve their ability to define appropriate combinations of myeloid malignancies and to isolate environmental risk factors that may be among their causes.

Nevertheless, our detailed evaluation of the four environmental chemical agents summarized here highlights important differences in risks by myeloid malignancies and provides support for reporting disease-specific findings from studies of environmental agents and risk of specific myeloid leukemias or other LHM. They also build on clinical observations that treatments with chemotherapy drugs lead to high incidence of AML and MDS (and possibly ALL) and that the genetic changes in therapy-related myeloid neoplasm reflect some specificity for the type of chemotherapy administered, but that chemotherapy does not lead to appreciable increases in CML, MPN, or lymphoid malignancies [2]. Meanwhile, epidemiological findings based on small numbers of specific LHM should be reported but appropriately caveated and not over-interpreted, as these results statistically will be unstable with likely false-positive and perhaps more likely false-negative relative risk estimates. Similarly, findings based on analyses of multiple types of leukemias and other LHM should be examined further and if possible, groups of LHM deconstructed, to identify the specific neoplasms that may be driving an observed association or situations where true associations may be diluted or masked.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-07908-3.

**Abbreviations**

aCML: Atypical chronic myeloid leukemia; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ANLL: Acute nonlymphocytic leukemia; B-cells: B lymphocytes; CI: Confidence interval; CLL: Chronic lymphocytic leukemia; CML: Chronic myeloid leukemia; CMML: Chronic myelomonocytic leukemia; cpd: Cigarettes per day; HFC: Hematopoietic progenitor cells; IARC: International Agency for Research on Cancer; JMML: Juvenile myelomonocytic leukemia; LHM: Lymphohematopoietic malignancies; m-RR: Meta-relative risk; MDS: Myelodysplastic syndrome (MDS); MPN: Myeloproliferative neoplasms; MDS/MPN: Myelodysplastic/myeloproliferative neoplasms; methyl-CCNU: semustine; MOPP: Vincristine-prednisone-nitrogen mustard-procarbazine; NHL: Non-Hodgkin lymphoma; NK cells: Natural killer cells; PMR: Proportionate mortality ratio; PPM: parts per million; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; pyrs: Pack-years; RR: Relative risk; SBR: Styrene–butadiene rubber; SMR: Standardized mortality ratio; T-cells: T lymphocyte; WHO: World Health Organization.

**Acknowledgments**

The authors gratefully acknowledge the valuable contributions and insights of Dr. Michael J. Thierman, University of Chicago Medical Center, on clinical and research aspects of myeloid malignancy and leukemia etiology. The authors also acknowledge the valuable assistance with the tables and calculations provided by Dr. Lynne P. Marshall, Cardno ChemRisk. The authors also thank the peer-reviewers for their careful review of the manuscript and insightful comments, which helped strengthen the manuscript.

**Authors’ contributions**

KAW, LD, PB and WJT substantially contributed to the conception and design of the work; EMB, HNL, CKL and VJD substantially contributed to the search, review, data extraction and statistical analysis; all authors contributed to the interpretation of findings, drafting and revising the manuscript. All authors read and approved the final manuscript.

**Funding**

This research was sponsored in part by a grant to Ramboll US Corporation from the Foundation for Chemistry Research and Initiatives (FCRI), a tax-exempt organization established by the American Chemistry Council (ACC) under Section 501(c)(3) of the Internal Revenue Code. The sponsors had no role in the design, conduct, analysis, interpretation or reporting.

**Availability of data and materials**

All data generated or analysed during this study are derived from publicly available peer-reviewed scientific publications and are presented in this article and its supplemental file.

**Ethics approval and consent to participate**

No human subjects were involved in this work. All data used were obtained from public sources, primarily the published scientific literature, and therefore consent to use these data was not required.

**Consent for publication**

Not applicable.

**Competing interests**

KAW, EMB, HNL, CKL and WJT are employed by Cardno ChemRisk and LD is employed by Ramboll US Consulting Inc., consulting firms that provide scientific advice to the government, corporations, law firms, and various scientific/professional organizations. Their contributions to the manuscript were part of their regular responsibilities with their respective employers. PB and VJD are academic professionals who generously contributed their time and expertise in preparing and reviewing the manuscript.

**Author details**

1Cardno ChemRisk, Boston, MA, USA. 2Ramboll US Consulting Inc, Amherst, MA, USA. 3Stony Brook Cancer Center, Stony Brook, NY, USA. 4Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 5Mount Sinai Hospital, New York, NY, USA.
multiple myeloma: a nationwide cohort study in Sweden. Cancer Res. 2007; 67(12):5983–6.
79. Ido M, Nagaoka C, Kawaike N, Shinmizu H, Yoshida Y, Nomura T, Mizoguchi H. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res. 1996;20(9):727–31.
80. Kabat GC, Augustine A, Hebert JR. Smoking and adult leukemia: a case-control study. J Clin Epidemiol. 1988;41(9):907–14.
81. Kabat GC, Wu JW, Moore SC, Morton LM, Park Y, Hellenbeck AR, Rohan TE. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomark Prev. 2013;22(5):488–54. https://doi.org/10.1158/1055-9965.EPI-13-0093.
82. Kameyama K, Romani E, Cartwright P, Parker J, Morgan G (1999) tobacco and the risk of acute leukemia in adults. Br J Cancer. 1999 Dec;81(7):1228–33.
83. Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16(5):489–500.
84. Kriloff ME, Murphy F, Pine E, Reeves GK, Green J, Beral V; Million Women Study Collaborators. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012;107(5):879–87. https://doi.org/10.1038/bjc.2012.333.
85. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Vining BA, Cerhan JR. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa women’s health study cohort. Int J Cancer. 2014;134(1):714–50. https://doi.org/10.1002/ijc.28460.
86. Linet MS, McLaughlin JK, Hsing AW, Wacholder S, Co-Chien HT, Shuman LM, Belfrage E, Blot WJ. Cigarette smoking and leukemia: results from the Lutheran brotherhood cohort study. Cancer Causes Control. 1991;2(6):413–7.
87. Lv L, Lin G, Gao X, Wu C, Dai J, Yang Y, Zou H, Sun H, Gu M, Chen X, Fu H, Bao L. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. Am J Hematol. 2011;86(2):163–9. https://doi.org/10.1002/ajh.21941.
88. Ma X, Lin U, Park Y, Mayne ST, Wang R, Hargreaves P, Hellenbeck AR, Schatzkin A. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol. 2009;169(12):1492–7. https://doi.org/10.1093/aje/kwp074.
89. Ma X, Park Y, Mayne ST, Wang R, Sinha R, Hellenbeck AR, Schatzkin A, Cross AJ. Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. Am J Epidemiol. 2010;171(3):312–22. https://doi.org/10.1093/aje/kwp571.
90. Mele A, Skölo M, Visani G, Stazi MA, Castelli G, Pasquini P, Mandelli F. Hair dye use and other risk factors for leukemia and pre-leukemia: a case-control study. Italian leukemia study group. Am J Epidemiol. 1994;139(3):609–19.
91. Mills PK, Newell GR, Beeson WL, Fraser GE, Phillips RL. History of cigarette smoking and risk of leukemia in a Japanese cohort. Cancer Res. 1999;59(3):609–16. https://doi.org/10.1158/0008-5472.CAN-98-0299.
92. Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013;37(4):410–6. https://doi.org/10.1016/j.canep.2013.07.003.
93. Nagata C, Shimizu H, Hiroshima K, Kakehashi E, Fujimura K, Niho Y, Karasawa H. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res. 1996;20(9):727–33.
94. Nisse C, Haguenoer JM, Grandbastien B, Preudhomme C, Fontaine B, Brillet J, Solal-Celigny P, Roques M, Bertain L. Lifestyle and environmental risk factors by subtypes of the WHO acute myeloid leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1993;85(24):1994–2003.
95. Parodi S, Merlo DF, Stagnaro E, Working Group for the Epidemiology and Regul Toxicol Pharmacol. 2018;92:472–8. https://doi.org/10.1016/j.toxpharm.2018.03.005.
96. Parodi S, Merlo DF, Stagnaro E, Working Group for the Epidemiology and Regul Toxicol Pharmacol. 2018;92:472–8. https://doi.org/10.1016/j.toxpharm.2018.03.005.
97. Petkuzova T, Svavajdik Vukovic N, Kisic D, Grigurevic A, Bogdanovic A, Gotic M, Bakrac M, Brkic N. A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro). Ann Hematol. 2000;85(5):14–9.
98. Pogoda JM, Preston-Martin S, Nichols PW, Ross RK. Smoking and risk of adult myeloid leukemia results from a Los Angeles County case-control study. Am J Epidemiol. 2002;156(5):546–53.
99. Richardson DB, Terschure C, Pohlken H, Jöckel KH, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control. 2008;19(1):43–50.
100. Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver RT, Weiss RB, Moore JD, Schiffier CA, et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1995;87(24):1994–2003.
101. Severson RK, Davis S, Heuser L, Daling JR, Thomas DB. Cigarette smoking and acute nonlymphocytic leukemia. Am J Epidemiol. 1990;132(3):418–22.
102. Speer SA, Semenza JC, Kurorasi T, Anton-Culver H. Risk factors for acute myeloid leukemia and multiple myeloma: a combination of GIS and case-control studies. J Environ Health. 2002;64(7):19–16.
103. Sengnaga E, Ramazzotti V, Cossignani P, Fontana A, Masala G, Milli L, Nanni O, Neri M, Rodella S, Costantini AS, Tumino R, Vignali C, Vindi C, Vines P. Smoking and hematolymphopoietic malignancies. Cancer Causes Control. 2001;12(4):325–34.
104. Strom SS, Oum R, Elhamb Gbry K, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118(18):4589–96. https://doi.org/10.1002/cncr.27442.
105. Uiqi T, Matsuo K, Sawada N, Iwashita M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center-based Prospective Study Group. Smoking and subsequent risk of leukemia in Japan: the Japan public health center-based prospective study. J Epidemiol. 2017a;27(7):305–10. https://doi.org/10.1096/j.aje.2016.07.005.
106. Uiqi T, Matsuo K, Sawada N, Iwashita M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Kanda Y, Tsugane S, Japan Public Health Centre-based Prospective Study Group. Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan public health centre-based prospective study. Br J Haematol. 2017b;178(5):747–55. https://doi.org/10.1111/bjh.14749.
107. Wakabayashi I, Sakamoto K, Masui H, Yoshimoto S, Kananarwa A, Kakisita F, Hara H, Shimo-oku M, Nagai K, Shimo-oka M. Smoking and acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118(18):4589–96. https://doi.org/10.1002/cncr.27442.
108. Wang O, Harris F, Yiying W, Hua F. A hospital-based case-control study of acute myeloid leukaemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol. 2009;55(3):340–52. https://doi.org/10.1016/j.yrtph.2009.08.007.
109. Xu X, Tallbott EO, Zborowski JV, Rager JR. Smoking and the risk of adult leukemia: results from the three Mile Island cohort study. Arch Environ Occup Health. 2007;62(3):131–7. https://doi.org/10.3200/ADOH.62.3.131-137.
110. Mundt KA, Gentry PR, Dell LD, Rodvics J, Bohettla P. Six years after the NRC review of EPA’s draft IRS toxicological review of formaldehyde: regulatory implications of new science in evaluating formaldehyde leukemogenicity. Regul Toxicol Pharmacol. 2018;92:472–90. https://doi.org/10.1016/j.yrtph.2017.11.006.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.